News

The company said that the complaint alleges that certain processes and methods performed by XenoTech associated with its in-vitro drug testing services and its pooled cryopreserved hepatocyte products,

The primary efficacy endpoint for Hokusai VTE is the recurrence of symptomatic VTE. The primary safety assessment of the trial is the incidence of major and clinically relevant

Dr Kobayashi will focus on expanding UBC’s operations in Japan with specific oversight on its line of services aimed at improving the reliability of clinical study results. Dr

The Elixia range of six products, including an Anti-oxidant Serum and a Multi V Moisturiser, uses the Phosphagenics’ patented TPM (Targeted Penetration Matrix) delivery technology to deliver more

Labopharm expects Oleptro to be available for prescription in the US later this year, with specific timing for its launch to be determined within the context of the

Reportedly, in 2006, Health Discovery has sued Ciphergen Biosystems in Federal District Court for infringement of several of its patents covering the use of support vector machines (SVMs)

Rik Deitsch, chairman and CEO of Nutra Pharma, said: “We were extremely pleased with our fourth quarter Cobroxin sales, especially given its initial limited retail availability. With the

Millipore’s fourth quarter earnings per share were $0.78 per share, compared to $0.56 per share in the fourth quarter of 2008. Non-GAAP earnings per share were $1.00, compared

The company said that the newly patented method extends the ability of the Entelos Metabolism PhysioLab platform to explore, simulate, and predict differences in fuel utilisation between patients,